Paige, a Sloan-Kettering spinout, is leader in computational pathology which is transforming the diagnosis and treatment of cancer.
Paige has been building an artificial intelligence platform to improve cancer pathology and subsequently use those insights to develop better drug therapies.
Paige was founded in 2017 by Dr. Thomas Fuchs and colleagues from Memorial Sloan Kettering Cancer Center. The company is headquartered in Franklin D Roosevelt Island, New York.
Paige has created an AI-native ecosystem that enables pathology teams to achieve higher quality, faster throughput and lower cost diagnoses and treatment recommendations. Additionally, Paige accelerates new biomarker discovery and its platform is designed to generate new insights into pathways and drug efficacy.
Paige is committed to delivering the technology in a way that integrates seamlessly with hospital and laboratory workflow systems and ensures safety, accuracy, security and data privacy.
Paige is backed by Breyer Capital, Casdin Capital, Goldman Sachs Merchant Banking Division, JJDC, HealthCor Partners and others. The company raised $100M in Series C round on Jan 14, 2021. This brings Paige's total funding to $190M to date.